Welcome to our dedicated page for KMTS news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KMTS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KMTS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KMTS's position in the market.
Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced the launch of its Initial Public Offering (IPO). The company plans to offer 10,000,000 common shares with an expected price range of $14.00 to $16.00 per share.
Underwriters will have a 30-day option to purchase up to 1,500,000 additional shares at the IPO price, less underwriting discounts and commissions. Kestra has applied to list on the Nasdaq Global Select Market under the symbol 'KMTS'.
The offering is led by BofA Securities, Goldman Sachs, and Piper Sandler as lead bookrunners, with Wells Fargo Securities and Stifel as bookrunners and Wolfe | Nomura Alliance as co-manager.
